DDrare: Database of Drug Development for Rare Diseases

Rapamycin, sirolimus (DrugBank: Sirolimus, Rapamycin)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
89	リンパ脈管筋腫症	1
158	結節性硬化症	1

89. リンパ脈管筋腫症　［臨床試験数：38，薬物数：42（DrugBank：19），標的遺伝子数：26，標的パスウェイ数：134］

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 38 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00457808 (ClinicalTrials.gov)	December 2002	6/4/2007	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: Rapamycin, sirolimus	Children's Hospital Medical Center, Cincinnati	The LAM Foundation;Tuberous Sclerosis Alliance	Completed	18 Years	65 Years	Both	25	Phase 2	United States

158. 結節性硬化症　［臨床試験数：100，薬物数：62（DrugBank：16），標的遺伝子数：35，標的パスウェイ数：115］

Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 100 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00457808 (ClinicalTrials.gov)	December 2002	6/4/2007	Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM	Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis	Tuberous Sclerosis;Lymphangioleiomyomatosis	Drug: Rapamycin, sirolimus	Children's Hospital Medical Center, Cincinnati	The LAM Foundation;Tuberous Sclerosis Alliance	Completed	18 Years	65 Years	Both	25	Phase 2	United States